Proven Efficacy
AGGRENOX prevents twice as many recurrent strokes as aspirin alone10*
AGGRENOX was proven effective in a large, multicenter, double-blind, placebo-controlled, prospective study of 6,602 patients—the European Stroke Prevention Study 2 (ESPS 2).
Read the evidence.
In ESPS 2, AGGRENOX reduced the relative risk of stroke by 37%, vs. 19% for aspirin.10*
* The ACCP and the American Heart Association recommend 50 mg-325 mg aspirin qd to reduce the risk of recurrent stroke and other vascular events.8, 9 In its required labeling (OTC), the FDA advises a dosage of 50 mg to 325 mg qd for patients with a history of TIA or stroke.20
AGGRENOX is twice as effective as aspirin at preventing recurrent stroke.










